Inflammatory Bowel Disease Treatment Market Size Expected to Reach USD 33.19 Bn by 2032
Ottawa, July 15, 2024 (GLOBE NEWSWIRE) -- The global inflammatory bowel disease treatment market size is predicted to increase from USD 19.91 billion in 2023 to approximately USD 33.19 billion by 2032, a study published by Towards Healthcare a sister firm of Precedence Statistics.
Download a short version of this report @ https://www.towardshealthcare.com/personalized-scope/5149
Key Takeaways
- North America led the market with the largest share in 2023. The region is observed to sustain the position during the forecast period.
- Asia Pacific is to grow at a notable rate during the forecast period.
- By type, the Crohn's disease segment led the market with the largest share in 2023.
- By drug class, the TNF inhibitors segment held a significant share of the inflammatory bowel disease treatment market.
- Crohn’s disease by disease type segment was the largest with over 61% market share in 2023.
- TNF inhibitors took the largest share in drug classes with a 32% market share in 2023.
- Retail pharmacies dominated the market with a 36% market share in 2023.
Inflammatory Bowel Disease Market at a Glance
Inflammatory Bowel Disease (IBD) is a chronic inflammation disorder of the gut and can be of two types: Crohn’s disease or ulcerative colitis. Crohn’s disease is characterized by ulcers and inflammation in the small intestine, whereas ulcerative colitis is characterized by ulcers and inflammation in the large intestine and rectum.
IBD can occur due to an immune response, genetic disorder, lifestyle changes, or inadequate nutrition. The treatment of IBD can only provide symptomatic relief but cannot completely cure the condition. The treatment regimen for IBD includes anti-diarrhoeal drugs, antispasmodics, immunomodulators, and corticosteroids.
Use of Combination Therapies as a Driver for Inflammatory Bowel Disease Treatment Market
Currently, biologicals like monoclonal antibodies or small molecules like anti-inflammatory agents are widely used for the treatment of IBD. However, multiple concurrent extraintestinal symptoms or other immune-mediated inflammatory illnesses may be more difficult to manage with biological agents used in monotherapy.
Hence, combination therapies are preferable alternatives to combating the disease. The combination therapies can result in an increase in therapeutic effectiveness associated with additive and synergistic effects by targeting different pathways simultaneously. The use of combination therapies can be a boost to the IBD treatment market.
Lack of Drugs to Cure IBD as a Restraint for the Inflammatory Bowel Disease Treatment Market
The current treatment options can reduce the inflammation but are unable to cure the disease. The complexity of the disease makes it difficult to discover novel drugs or biologics for the complete cure of the disease. IBD is caused by a very complicated interaction between genetics and the environment. That makes determining the best course of action extremely challenging. This lack of treatment options can act as a restraint on the IBD treatment market.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
North America Led in 2023 and to Act as a Leader for the Market in the Upcoming Years
The North American region has the highest potential for IBD treatment market growth. The higher prevalence rates and advanced research and development facilities can drive the IBD treatment market in this region. Countries like the US and Canada report the highest number of IBD cases globally.
According to the Crohn’s and Colitis Foundation, approximately 2.6 million cases were reported in the US in 2023. The FDA approval of novel molecules offers a huge scope for market growth. This, in turn, encourages collaborations and partnerships for cutting-edge research to improve IBD diagnosis and treatment in the region.
- In March 2022, the USFDA approved a novel JAK inhibitor, upadacitinib, for the treatment of moderate to severe ulcerative colitis. AbbVie, an American pharmaceutical company, developed this novel inhibitor.
Asia-Pacific is expected to grow at a notable rate in the inflammatory bowel disease treatment market during the forecast period. China reports the highest number of IBD cases after the US. China’s fast industrialization and urbanization have exposed genetically vulnerable people to modernized environmental elements that could change their gut microbiota.
Additionally, economic advancements lead to increased knowledge among patients and clinicians, better illness surveillance, increased availability of diagnostic instruments, and better access to healthcare systems, increasing the prevalence of IBD cases. All these factors drive the market's growth potential.
- In June 2024, AbbVie, the US pharmaceutical firm, and FutureGen Biopharmaceutical, a Chinese firm, signed an agreement for the development of FG-M701. It is a next-generation TL1A antibody for the treatment of IBD.
Europe also has the potential for IBD treatment market growth. The prevalence rates in Western European countries like Scandinavia, the UK, Norway, Sweden, and Denmark are increasing. The rising prevalence rates and increasing trend of innovations in therapeutics are the driving factors of the IBD treatment market in Europe.
- In December 2023, the European Medicines Agency approved the drug Velsipity developed by Pfizer. The drug was developed for the treatment of IBD for patients of 16 years or older with no response to the previous treatment.
Customize this study as per your requirement @ https://www.towardshealthcare.com/customization/5149
Stem Cell Therapy as an Opportunity for Inflammatory Bowel Disease Treatment Market
Stem cells can differentiate and proliferate various tissue cells through secretory functions. Stem cell therapy for IBD has demonstrated remarkable potential for treating this condition. Mesenchymal stem cells (MSCs) have been investigated for treating IBD. MSCs may aid in reducing inflammation and preventing gastrointestinal injury by regulating the immune system and encouraging tissue regeneration. The use of stem cells as a treatment for ulcerative colitis patients may grow in popularity.
The Crohn’s Disease Segment is Observed to Sustain as a Leading Segment in the Market
The rising incidence of Crohn's disease globally has heightened the demand for effective treatments and management strategies. Innovations in biologics and other advanced therapies have improved treatment outcomes for Crohn’s disease, attracting more investments and research. Crohn's disease is a chronic condition requiring long-term management, leading to sustained demand for medications and healthcare services.
Under the Drug Class Category, the TNF Inhibitors Segment Led the Market in 2023
TNF inhibitors have proven highly effective in managing autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis, leading to their widespread adoption. The increasing incidence of autoimmune conditions has driven demand for effective treatments like TNF inhibitors. TNF inhibitors often offer convenient dosing schedules and delivery methods, enhancing patient adherence to treatment regimens.
Browse More Insights of Towards Healthcare:
- The global legal marijuana market size was valued at $30.75 billion in 2023 and is projected $113.26 billion by 2033, registered a at 14.4% of CAGR from 2023 to 2033.
- The global sports medicine market size was valued at USD 5.89 billion in 2023 and is to hit USD 10.82 billion by 2033, expanding at a 6.6% of CAGR from 2023 to 2033.
- The global computational biology market size was estimated at US$ 5.60 billion in 2023 and is projected to grow US$ 19.35 billion by 2033, rising at a compound annual growth rate (CAGR) of 13.20% from 2024 to 2033.
- The global mHealth market size was valued at USD 60.65 billion in 2023 and is to hit USD 176.54 billion by 2033, expanding at a CAGR of 11.6% from 2023 to 2033.
- The global home healthcare market size was valued at USD 192.4 billion in 2023 and is projected USD 427.69 billion by 2033, increasing at a 8.6% of CAGR from 2023 to 2033.
- The global biomaterials market size was estimated at US$ 178.16 billion in 2023 and is projected to grow US$ 761.23 billion by 2033, rising at a compound annual growth rate (CAGR) of 15.63% from 2024 to 2033.
- The global telehealth and telemedicine market size surpassed $ 214.55 billion in 2023 to reach $ 869.22 billion by 2033, growing at a 15.5% CAGR between 2023 and 2033.
- The global advanced drug delivery market size was valued at USD 234.84 billion in 2023 and is to hit USD 375.86 billion by 2033, growing at a 4.6% CAGR from 2023 to 2033.
- The osteoarthritis market is to rise from USD 8.60 billion in 2023 to reach around USD 19.15 billion by 2032, increasing at a CAGR of 8.4% during the period from 2024 to 2032.
- The carpal tunnel syndrome market size is expected to increase from USD 942.69 million in 2023 to about USD 1328.69 million by 2032, growing at a CAGR of 3.7% between 2024 and 2032.
Major Breakthroughs in the Inflammatory Bowel Disease Treatment Market:
- In July 2024, PharmassêtX Inc. announced that the USFDA granted an orphan drug designation to epigallocatechin gallate, a green tea component, for treating pouchitis, a rare form of IBD. The company is working on increasing the drug’s potency for treating pouchitis.
- In July 2024, Eli Lily and Company announced plans to acquire Morphic Therapeutics, which is currently developing a small molecule to treat IBD. MORF-057, an α4β7 integrin inhibitor, is in Phase 2 trials for treating moderate to severe active Crohn’s disease.
- In June 2024, engineers from the University of California, San Diego, developed microbots for the symptomatic relief of IBD and tested them on mice. The microbots contained proinflammatory cytokine nanoparticles and green algae, which, when administered orally, dispersed into the colon and absorbed the cytokines, ultimately reducing the inflammation locally.
Top Companies in the Inflammatory Bowel Disease Treatment Market:
- Arena Pharmaceuticals
- AbbVie
- Pfizer
- Abivax
- Eli Lilly and Company
- Merck Sharp and Dohme LLC
- Janssen
- Ferring Pharmaceuticals
- Alkem Laboratories
Inflammatory Bowel Disease Treatment Market Segments
(**We also provide cross-sectional analysis in market segments)
By Type
- Crohn's Disease
- Ulcerative Colitis
By Drug Class
- Corticosteroids
- Aminosalicylates
- TNF Inhibitors
- IL Inhibitors
- JAK Inhibitors
- Anti-Integrin
- Others
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Geography
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- South America
Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5149
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Browse our Brand-New Journals:
https://www.towardspackaging.com
https://www.towardsautomotive.com
https://www.precedenceresearch.com
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Get Our Freshly Printed Chronicle: https://www.healthcarewebwire.com
© Copyright Globe Newswire, Inc. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire, Inc.
